Parikh Anand Kiran 4

What Happened

• Anand Kiran Parikh, Chief Operating Officer of Sensei Biotherapeutics (SNSE), was granted/received an aggregate of 2,198,333 shares of Series B Non-Voting Convertible Preferred Stock (derivative) in transactions reported Feb 17–19, 2026. The filing shows multiple grants: 809,822; 92,533; 56,673 (all reported Feb 17) and 1,239,305 (reported Feb 19 at $0.00). These were awards/consideration tied to a merger and option exchanges rather than open-market purchases or cash payments.
• Each Series B Preferred share is convertible into 1,000 shares of Sensei common stock (per the filing), so these preferred shares represent the potential to convert into approximately 2.198 billion common shares. The Series B Preferred has no expiration date and the immediate reported cash value is $0.00 / N/A in the filing.

Key Details

• Transaction dates: Feb 17, 2026 (three grants: 809,822; 92,533; 56,673) and Feb 19, 2026 (1,239,305 at $0.00). Filing date: Feb 19, 2026.
• Reported price: N/A for three grants; $0.00 for the Feb 19 grant (derivative issuance/merger consideration).
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Notable footnotes from the filing:
  • F1: Each Series B Preferred share converts into 1,000 common shares; Preferred has no expiration.
  • F2–F4, F6: Portions were received in exchange for HoldCo/Faeth common shares and for Faeth stock options (some options had a $0.23 exercise price prior to exchange).
  • F5, F7, F8: Vesting/exercisability terms vary — some shares/options are immediately exercisable; others vest 25% on Feb 19, 2027 with the remainder vesting monthly over 36 months.
• Timeliness: Filing was submitted Feb 19, 2026 for transactions on Feb 17–19, 2026 (no late-filing indication in the excerpt).

Context

• These transactions are merger consideration and equity awards/exchanges tied to Sensei’s acquisition of Faeth/HoldCo interests, not open-market insider buying or selling. That means they reflect deal-related compensation/conversion rather than a direct vote of confidence via personal cash purchases.
• The convertible preferred structure creates substantial potential dilution if converted (1 preferred → 1,000 common). For investors, note the difference between receiving convertible preferred/security awards and straightforward purchases or sales of listed common stock.
• As always, these filings are factual disclosures of holdings/transactions; they do not state the insider’s motives.